RTP Mobile Logo
Renal Cell Cancer Update, Issue 1, 2010
Released October 2010

Featuring interviews with Drs Eric Jonasch, David I Quinn, David F McDermott and Bernard J Escudier. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Advances in the biologic understanding of renal cell cancer (RCC) and the emergence of clinical trial data with targeted therapeutic agents have resulted in the availability of novel treatment strategies for this challenging disease. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical or urologic oncologist must be well informed of these rapidly evolving data sets. To bridge the gap between research and patient care, Renal Cell Cancer Update utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME activity assists medical and urologic oncologists with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Apply an understanding of the biology of advanced RCC, including inactivation of the von Hippel-Lindau tumor suppressor gene and the pathway leading to VEGF overexpression, to therapeutic decision-making.
    • Identify patient characteristics that may help to distinguish the individualized utility of nephrectomy in the era of effective targeted therapies for metastatic renal cell carcinoma (mRCC).
    • Apply the results of existing and emerging clinical research to the evidence-based selection of front-line and subsequent therapy for mRCC.
    • Develop an approach for the sequencing of therapies for advanced RCC, incorporating biologic response modifiers, tyrosine kinase inhibitors (TKIs), anti-VEGF antibodies and mTOR inhibitors.
    • Educate patients with mRCC about the safety and tolerability of VEGF TKIs, mTOR inhibitors and VEGF monoclonal antibody therapy.
    • Recommend supportive measures to enhance the tolerability of targeted therapeutic agents for RCC, including the use of dose reductions, schedule changes or alternative therapies.
    • Counsel appropriately selected patients with RCC about the availability of ongoing clinical trial participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY


    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CONTENT VALIDATION AND DISCLOSURES


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr JonaschAdvisory Committee: Bayer HealthCare Pharmaceuticals; Consulting Agreements: Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr QuinnAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Research Support: Millennium Pharmaceuticals Inc. Dr McDermottAdvisory Committee: Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology, Genzyme Corporation, GlaxoSmithKline, Roche Laboratories Inc; Consulting Agreements: Biogen Idec, Wyeth. Dr Escudier Consulting Agreements and Honoraria: AVEO Pharmaceuticals, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc.

    EDITOR
    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc and Genentech BioOncology.


    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2010
    Expiration date: October 2011

Acknowledge and close

Renal Cell Cancer Update, Issue 1, 2010
Released October 2010

Featuring interviews with Drs Eric Jonasch, David I Quinn, David F McDermott and Bernard J Escudier. (Audio Content)